Literature DB >> 19874535

Evidence-based interventional pain medicine according to clinical diagnoses. 3. Persistent idiopathic facial pain.

Paul Cornelissen1, Maarten van Kleef, Nagy Mekhail, Miles Day, Jan van Zundert.   

Abstract

Persistent idiopathic facial pain, previously known as atypical facial pain, is described as a persistent facial pain that does not have the classical characteristics of cranial neuralgias and for which there is no obvious cause (International Classification of Headache Disorders in 2004). According to these criteria, the diagnosis is possible if the facial pain is localized, present daily, and throughout all or most of the day. By definition, neurological and physical examination findings in persistent idiopathic facial pain should be normal. Forming a diagnosis is not simple and follows a process of elimination of other causes of facial pain. The precise incidence is unknown. The affliction is seen primarily in older adults and rarely in children. The pathophysiology is unknown. In persistent idiopathic facial pain, there is no abnormal processing of somatosensory stimuli in the pain area or facial area of the primary somatosensory cortex of the brain. The treatment is difficult and often requires a multidisciplinary approach. The most important part of the treatment is psychological counseling and pharmacological therapy. Pharmacological treatment with tricyclic antidepressants and anti-epileptic drugs can be tried. The conservative, pharmacological treatment with amitryptiline is the primary choice. Venlafaxine and fluoxetine treatment can also be considered. When the pharmacological treatment fails, pulsed radiofrequency treatment of the ganglion pterygopalatinum (sphenopalatinum) can be considered (2 C+).

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19874535     DOI: 10.1111/j.1533-2500.2009.00332.x

Source DB:  PubMed          Journal:  Pain Pract        ISSN: 1530-7085            Impact factor:   3.183


  8 in total

Review 1.  Pulsed radiofrequency treatment in interventional pain management: mechanisms and potential indications-a review.

Authors:  Nicholas H L Chua; Kris C Vissers; Menno E Sluijter
Journal:  Acta Neurochir (Wien)       Date:  2010-11-30       Impact factor: 2.216

Review 2.  Atypical Facial Pain: a Comprehensive, Evidence-Based Review.

Authors:  Austin L Weiss; Ken P Ehrhardt; Reda Tolba
Journal:  Curr Pain Headache Rep       Date:  2017-02

Review 3.  Interventional procedures for facial pain.

Authors:  Kevin E Vorenkamp
Journal:  Curr Pain Headache Rep       Date:  2013-01

Review 4.  Interventional Radiofrequency Treatment for the Sympathetic Nervous System: A Review Article.

Authors:  Nicholas A Zacharias; Jay Karri; Carol Garcia; Laura K Lachman; Alaa Abd-Elsayed
Journal:  Pain Ther       Date:  2021-01-12

5.  Long-term results of therapeutic local anesthesia (neural therapy) in 280 referred refractory chronic pain patients.

Authors:  Simon Egli; Mirjam Pfister; Sabina M Ludin; Katia Puente de la Vega; André Busato; Lorenz Fischer
Journal:  BMC Complement Altern Med       Date:  2015-06-27       Impact factor: 3.659

Review 6.  "Evidence-Based Interventional Pain Medicine According to Clinical Diagnoses": Update 2018.

Authors:  Frank Huygen; Jan Willem Kallewaard; Maurits van Tulder; Koen Van Boxem; Kris Vissers; Maarten van Kleef; Jan Van Zundert
Journal:  Pain Pract       Date:  2019-05-02       Impact factor: 3.183

7.  Notalgia paresthetica: clinical features, radiological evaluation, and a novel therapeutic option.

Authors:  Cevriye Mülkoğlu; Barış Nacır
Journal:  BMC Neurol       Date:  2020-05-16       Impact factor: 2.474

8.  Differences in the Clinical Characteristics of Persistent Idiopathic Facial Pain (Atypical Odontalgia) Patients with or Without Neurovascular Compression of the Trigeminal Nerve.

Authors:  Kaoru Kawasaki; Shiori Sugawara; Kazuya Watanabe; Chaoli Hong; Trang Thi Huyen Tu; Takeshi Watanabe; Junichiro Sakamoto; Norio Yoshino; Takayuki Suga; Lou Mikuzuki; Miho Takenoshita; Satoshi Takada; Tohru Kurabayashi; Akira Toyofuku
Journal:  Pain Med       Date:  2020-04-01       Impact factor: 3.750

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.